Novel mutation of the activation-induced cytidine deaminase gene in a Tajik family: Special review on hyper-immunoglobulin M syndrome

Expert Review of Clinical Immunology

Volumn 8, Issue 6, 2012, Pages 539-546

  Mahdaviani, Seyed Alireza ^a   Hirbod Mobarakeh, Armin ^b,c   Wang, Ning ^d   Aghamohammadi, Asghar ^c   Hammarström, Lennart ^d   Masjedi, Mohammad Reza ^e   Pan Hammarström, Qiang ^d   Rezaei, Nima ^b,c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

activation induced cytidine deaminase; hyper immunoglobulin M; mutation

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE;

AUTOSOMAL RECESSIVE INHERITANCE; DISEASE ASSOCIATION; GENE MUTATION; GENETIC ASSOCIATION; HYPER IGM SYNDROME; MUTATIONAL ANALYSIS; PHENOTYPE; PUBLISHING; REVIEW; SIBLING; TAJIKISTAN;

CHILD, PRESCHOOL; CYTIDINE DEAMINASE; FEMALE; HUMANS; HYPER-IGM IMMUNODEFICIENCY SYNDROME; MALE; MUTATION, MISSENSE; SIBLINGS; YOUNG ADULT;

EID: 84866675051     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.46     Document Type: Review

References (41)

1. Davies EG, Thrasher AJ. Update on the hyper immunoglobulin M syndromes. Br. J. Haematol. 149(2), 167-180 (2010).
2. Erdos M, Durandy A, Maródi L. Genetically acquired class-switch recombination defects: the multi-faced hyper-IgM syndrome. Immunol. Lett. 97(1), 1-6 (2005).
3. Erdos M, Garami M, Rákóczi E et al. Neuroendocrine carcinoma associated with X-linked hyper-immunoglobulin M syndrome: report of four cases and review of the literature. Clin. Immunol. 129(3), 455-461 (2008).
4. Kashef S, Ghaedian MM, Rezaei N et al. Isolated growth hormone deficiency in a patient with immunoglobulin class switch recombination deficiency. J. Investig. Allergol. Clin. Immunol. 19(3), 233-236 (2009).
5. Jesus AA, Duarte AJ, Oliveira JB. Autoimmunity in hyper-IgM syndrome. J. Clin. Immunol. 28(Suppl. 1), S62-S66 (2008).
6. Quartier P, Bustamante J, Sanal O et al. Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to activationinduced cytidine deaminase deficiency. Clin. Immunol. 110(1), 22-29 (2004).
7. Rezaei N, Aghamohammadi A, Ramyar A, Pan-Hammarstrom Q, Hammarstrom L. Severe congenital neutropenia or hyper-IgM syndrome? A novel mutation of CD40 ligand in a patient with severe neutropenia. Int. Arch. Allergy Immunol. 147(3), 255-259 (2008).
8. Aghamohammadi A, Parvaneh N, Rezaei N et al. Clinical and laboratory findings in hyper-IgM syndrome with novel CD40L and AICDA mutations. J. Clin. Immunol. 29(6), 769-776 (2009).
9. Rezaei N, Pourpak Z, Aghamohammadi A et al. Consanguinity in primary immunodeficiency disorders; the report from Iranian Primary Immunodeficiency Registry. Am. J. Reprod. Immunol. 56(2), 145-151 (2006).
10. Rezaei N, Aghamohammadi A, Moin M et al. Frequency and clinical manifestations of patients with primary immunodeficiency disorders in Iran: update from the Iranian Primary Immunodeficiency Registry. J. Clin. Immunol. 26(6), 519-532 (2006).
11. Fiorini C, Jilani S, Losi CG et al. A novel activation-induced cytidine deaminase gene mutation in a Tunisian family with hyper IgM syndrome. Eur. J. Pediatr. 163(12), 704-708 (2004).
12. Revy P, Muto T, Levy Y et al. Activationinduced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell 102(5), 565-575 (2000).
13. Muramatsu M, Sankaranand VS, Anant S et al. Specific expression of activationinduced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J. Biol. Chem. 274(26), 18470-18476 (1999).
14. Erdos M, Alapi K, Maródi L. Retrospective diagnosis of X-linked hyper-IgM syndrome in a family with multiple deaths of affected males. Haematologica 92(2), 281-282 (2007).
15. Ferrari S, Plebani A. Cross-talk between CD40 and CD40L: lessons from primary immune deficiencies. Curr. Opin. Allergy Clin. Immunol. 2(6), 489-494 (2002).
16. Tomizawa D, Imai K, Ito S et al. Allogeneic hematopoietic stem cell transplantation for seven children with X-linked hyper-IgM syndrome: a single center experience. Am. J. Hematol. 76(1), 33-39 (2004).
17. Durandy A, Peron S, Taubenheim N, Fischer A. Activation-induced cytidine deaminase: structure-function relationship as based on the study of mutants. Hum. Mutat. 27(12), 1185-1191 (2006).
18. Thusberg J, Vihinen M. The structural basis of hyper IgM deficiency-CD40L mutations. Protein Eng. Des. Sel. 20(3), 133-141 (2007).
19. Lee WI, Torgerson TR, Schumacher MJ, Yel L, Zhu Q, Ochs HD. Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome. Blood 105(5), 1881-1890 (2005).
20. Shivarov V, Shinkura R, Honjo T. Dissociation of in vitro DNA deamination activity and physiological functions of AID mutants. Proc. Natl Acad. Sci. USA 105(41), 15866-15871 (2008).
21. Begum NA, Kinoshita K, Muramatsu M, Nagaoka H, Shinkura R, Honjo T. De novo protein synthesis is required for activationinduced cytidine deaminase-dependent DNA cleavage in immunoglobulin class switch recombination. Proc. Natl Acad. Sci. USA 101(35), 13003-13007 (2004).
22. Shivarov V, Shinkura R, Doi T et al. Molecular mechanism for generation of antibody memory. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 364(1517), 569-575 (2009).
23. Petersen-Mahrt SK, Harris RS, Neuberger MS. AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature 418(6893), 99-103 (2002).
24. Xu Z, Pone EJ, Al-Qahtani A, Park SR, Zan H, Casali P. Regulation of aicda expression and AID activity: relevance to somatic hypermutation and class switch DNA recombination. Crit. Rev. Immunol. 27(4), 367-397 (2007).
25. Ta VT, Nagaoka H, Catalan N et al. AID mutant analyses indicate requirement for class-switch-specific cofactors. Nat. Immunol. 4(9), 843-848 (2003).
26. Shinkura R, Ito S, Begum NA et al. Separate domains of AID are required for somatic hypermutation and class-switch recombination. Nat. Immunol. 5(7), 707-712 (2004).
27. Navaratnam N, Morrison JR, Bhattacharya S et al. The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase. J. Biol. Chem. 268(28), 20709-20712 (1993).
28. Minegishi Y, Lavoie A, Cunningham-Rundles C et al. Mutations in activationinduced cytidine deaminase in patients with hyper IgM syndrome. Clin. Immunol. 97(3), 203-210 (2000).
29. Mir Saeid Ghazi B, Aghamohammadi A, Kouhi A et al. Mortality in primary immunodeficient patients, registered in Iranian primary immunodeficiency registry. Iran. J. Allergy. Asthma. Immunol. 3(1), 31-36 (2004).
30. Micol R, Kayal S, Mahlaoui N et al. Protective effect of IgM against colonization of the respiratory tract by nontypeable Haemophilus influenzae in patients with hypogammaglobulinemia. J. Allergy Clin. Immunol. 129(3), 770-777 (2012).
31. Piirilä H, Väliaho J, Vihinen M. Immunodeficiency mutation databases (IDbases). Hum. Mutat. 27(12), 1200-1208 (2006).
32. Keerthikumar S, Raju R, Kandasamy K et al. RAPID: Resource of Asian Primary Immunodeficiency Diseases. Nucleic Acids Res. 37, D863-D867 (2009).
33. Zhu Y, Nonoyama S, Morio T, Muramatsu M, Honjo T, Mizutani S. Type two hyper-IgM syndrome caused by mutation in activation-induced cytidine deaminase. J. Med. Dent. Sci. 50(1), 41-46 (2003).
34. Erdos M, Lakos G, Dérfalvi B, Notarangelo LD, Durandy A, Maródi L. Molecular genetic analysis of Hungarian patients with the hyper-immunoglobulin M syndrome. Mol. Immunol. 45(1), 278-282 (2008).
35. Facchetti F, Appiani C, Salvi L, Levy J, Notarangelo LD. Immunohistologic analysis of ineffective CD40-CD40 ligand interaction in lymphoid tissues from patients with X-linked immunodeficiency with hyper-IgM. Abortive germinal center cell reaction and severe depletion of follicular dendritic cells. J. Immunol. 154(12), 6624-6633 (1995).
36. Noguchi E, Shibasaki M, Inudou M et al. Association between a new polymorphism in the activation-induced cytidine deaminase gene and atopic asthma and the regulation of total serum IgE levels. J. Allergy Clin. Immunol. 108(3), 382-386 (2001).
37. Kasahara Y, Kaneko H, Fukao T et al. Hyper-IgM syndrome with putative dominant negative mutation in activationinduced cytidine deaminase. J. Allergy Clin. Immunol. 112(4), 755-760 (2003).
38. Imai K, Zhu Y, Revy P et al. Analysis of class switch recombination and somatic hypermutation in patients affected with autosomal dominant hyper-IgM syndrome type 2. Clin. Immunol. 115(3), 277-285 (2005).
39. Barreto V, Reina-San-Martin B, Ramiro AR, McBride KM, Nussenzweig MC. C-terminal deletion of AID uncouples class switch recombination from somatic hypermutation and gene conversion. Mol. Cell 12(2), 501-508 (2003).
40. Doi T, Kato L, Ito S et al. The C-terminal region of activation-induced cytidine deaminase is responsible for a recombination function other than DNA cleavage in class switch recombination. Proc. Natl Acad. Sci. USA 106(8), 2758-2763 (2009).
41. Ito S, Nagaoka H, Shinkura R et al. Activation-induced cytidine deaminase shuttles between nucleus and cytoplasm like apolipoprotein B mRNA editing catalytic polypeptide 1. Proc. Natl Acad. Sci. USA 101(7), 1975-1980 (2004).